Maravai LifeSciences Holdings, Inc.
MRVI
$1.77
$0.052.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -10.30% | -33.99% | -48.78% | -61.81% | -67.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.30% | -33.99% | -48.78% | -61.81% | -67.28% |
| Cost of Revenue | 1.43% | -10.99% | -11.86% | -5.66% | -11.96% |
| Gross Profit | -22.75% | -49.18% | -65.33% | -78.26% | -80.37% |
| SG&A Expenses | 9.83% | 5.65% | 11.65% | 14.27% | 20.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.92% | -4.53% | -2.31% | 2.24% | 1.14% |
| Operating Income | -198.27% | -156.16% | -120.45% | -111.64% | -104.25% |
| Income Before Tax | -142.33% | 668.30% | 210.97% | 57.81% | 12.02% |
| Income Tax Expenses | -100.25% | 47,572.98% | 4,123.28% | 1,917.25% | 1,143.42% |
| Earnings from Continuing Operations | -87.62% | -647.31% | -193.36% | -146.64% | -128.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 493.28% | 385.59% | 130.70% | 115.15% | 107.15% |
| Net Income | -21.69% | -1,014.59% | -274.96% | -185.49% | -154.05% |
| EBIT | -198.27% | -156.16% | -120.45% | -111.64% | -104.25% |
| EBITDA | -252.96% | -99.13% | -99.17% | -100.89% | -97.37% |
| EPS Basic | -14.44% | -982.55% | -273.90% | -185.12% | -153.82% |
| Normalized Basic EPS | -87.55% | 80,834.09% | 1,968.14% | 804.58% | 453.52% |
| EPS Diluted | -14.36% | -987.51% | -274.13% | -185.73% | -154.34% |
| Normalized Diluted EPS | -87.55% | 80,834.09% | 1,969.53% | 1,067.73% | 710.48% |
| Average Basic Shares Outstanding | 4.52% | 2.79% | 1.04% | 0.35% | 0.28% |
| Average Diluted Shares Outstanding | 4.52% | 2.79% | 1.01% | -18.78% | -31.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |